<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31796494</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>31</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>12</Issue><PubDate><Year>2019</Year><Month>Dec</Month><Day>02</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients.</ArticleTitle><Pagination><StartPage>e033131</StartPage><MedlinePgn>e033131</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e033131</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2019-033131</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Amyotrophic lateral sclerosis (ALS) is a progressive and severe neurodegenerative disease caused by motor neuron death. There have as yet been no fundamental curative medicines, and the development of a medicine for ALS is urgently required. Induced pluripotent stem cell (iPSC)-based drug repurposing identified an Src/c-Abl inhibitor, bosutinib, as a candidate molecular targeted therapy for ALS. The objectives of this study are to evaluate the safety and tolerability of bosutinib for the treatment of patients with ALS and to explore the efficacy of bosutinib on ALS. This study is the first clinical trial of administered bosutinib for patients with ALS.</AbstractText><AbstractText Label="METHODS AND ANALYSIS">An open-label, multicentre phase I dose escalation study has been designed. The study consists of a 12-week observation period, a 1-week transitional period, a 12-week study treatment period and a 4-week follow-up period. After completion of the transitional period, subjects whose total ALS Functional Rating Scale-Revised (ALSFRS-R) score decreased by 1-3 points during the 12-week observation period receive bosutinib for 12 weeks. Three to six patients with ALS are enrolled in each of the four bosutinib dose levels (100, 200, 300 or 400&#x2009;mg/day) to evaluate the safety and tolerability under a 3+3&#x2009;dose escalation study design. Dose escalation and maximum tolerated dose are determined by the safety assessment committee comprising oncologists/haematologists and neurologists based on the incidence of dose-limiting toxicity in the first 4 weeks of the treatment at each dose level. A recommended phase II dose is determined by the safety assessment committee on completion of the 12-week study treatment in all subjects at all dose levels. The efficacy of bosutinib is also evaluated exploratorily using ALS clinical scores and biomarkers.</AbstractText><AbstractText Label="ETHICS AND DISSEMINATION">This study received full ethical approval from the institutional review board of each participating site. The findings of the study will be disseminated in peer-reviewed journals and at scientific conferences.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER">UMIN000036295; Pre-results, JMA-IIA00419; Pre-results.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Imamura</LastName><ForeName>Keiko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Izumi</LastName><ForeName>Yuishin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banno</LastName><ForeName>Haruhiko</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uozumi</LastName><ForeName>Ryuji</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-9546-9869</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Statistics and Bioinformatics, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morita</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biomedical Statistics and Bioinformatics, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Egawa</LastName><ForeName>Naohiro</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayaki</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagai</LastName><ForeName>Makiko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kitasato University School of Medicine, Sagamihara, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishiyama</LastName><ForeName>Kazutoshi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kitasato University School of Medicine, Sagamihara, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Yonago, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanajima</LastName><ForeName>Ritsuko</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Yonago, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oki</LastName><ForeName>Ryosuke</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujita</LastName><ForeName>Koji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Naoto</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikeda</LastName><ForeName>Takafumi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimizu</LastName><ForeName>Akira</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morinaga</LastName><ForeName>Akiko</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pfizer R&amp;D Japan G.K, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirohashi</LastName><ForeName>Tomoko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Pfizer R&amp;D Japan G.K, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujii</LastName><ForeName>Yosuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Pfizer R&amp;D Japan G.K, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Ryosuke</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inoue</LastName><ForeName>Haruhisa</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-4736-9537</Identifier><AffiliationInfo><Affiliation>Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan haruhisa@cira.kyoto-u.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>JPRN</DataBankName><AccessionNumberList><AccessionNumber>UMIN000036295</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>12</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009570">Nitriles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011804">Quinolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>5018V4AEZ0</RegistryNumber><NameOfSubstance UI="C471992">bosutinib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017321" MajorTopicYN="N">Clinical Trials, Phase I as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="N">Drug Repositioning</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009570" MajorTopicYN="N">Nitriles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039904" MajorTopicYN="N">Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011804" MajorTopicYN="N">Quinolines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">bosutinib</Keyword><Keyword MajorTopicYN="N">drug repositioning/ repurposing</Keyword><Keyword MajorTopicYN="N">induced pluripotent stem cell</Keyword><Keyword MajorTopicYN="N">molecular targeted therapy</Keyword></KeywordList><CoiStatement>Competing interests: The study drug bosutinib and the pharmacokinetic analysis for only subject-experienced serious adverse events are supported by Pfizer JAPAN under the Clinical Research Collaboration Agreement. RT and NT received research funding and honoraria for lectures from Pfizer.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31796494</ArticleId><ArticleId IdType="pmc">PMC7003406</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2019-033131</ArticleId><ArticleId IdType="pii">bmjopen-2019-033131</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Marin B, Boum&#xe9;diene F, Logroscino G, et al. . Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. Int J Epidemiol 2017;46:57&#x2013;74. 10.1093/ije/dyw061</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyw061</ArticleId><ArticleId IdType="pmc">PMC5407171</ArticleId><ArticleId IdType="pubmed">27185810</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura R, Sone J, Atsuta N, et al. . Next-Generation sequencing of 28 ALS-related genes in a Japanese ALS cohort. Neurobiol Aging 2016;39:219.e1&#x2013;219.e8. 10.1016/j.neurobiolaging.2015.11.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.11.030</ArticleId><ArticleId IdType="pubmed">26742954</ArticleId></ArticleIdList></Reference><Reference><Citation>Finsterer J, Burgunder J-M. Recent progress in the genetics of motor neuron disease. Eur J Med Genet 2014;57:103&#x2013;12. 10.1016/j.ejmg.2014.01.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmg.2014.01.002</ArticleId><ArticleId IdType="pubmed">24503148</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurel C, Dangoumau A, Marouillat S, et al. . Causative genes in amyotrophic lateral sclerosis and protein degradation pathways: a link to neurodegeneration. Mol Neurobiol 2018;55:6480&#x2013;99. 10.1007/s12035-017-0856-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-017-0856-0</ArticleId><ArticleId IdType="pubmed">29322304</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V, et al. . A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994;330:585&#x2013;91. 10.1056/NEJM199403033300901</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Aoki M, Tsuji S, et al. . Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. The Lancet Neurology 2017;16:505&#x2013;12. 10.1016/S1474-4422(17)30115-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura K, Izumi Y, Watanabe A, et al. . The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci Transl Med 2017;9 10.1126/scitranslmed.aaf3962</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf3962</ArticleId><ArticleId IdType="pubmed">28539470</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenqiang C, Lonskaya I, Hebron ML, et al. . Parkin-Mediated reduction of nuclear and soluble TDP-43 reverses behavioral decline in symptomatic mice. Hum Mol Genet 2014;23:4960&#x2013;9. 10.1093/hmg/ddu211</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu211</ArticleId><ArticleId IdType="pubmed">24847002</ArticleId></ArticleIdList></Reference><Reference><Citation>Lonskaya I, Hebron ML, Desforges NM, et al. . Tyrosine kinase inhibition increases functional parkin-Beclin-1 interaction and enhances amyloid clearance and cognitive performance. EMBO Mol Med 2013;5:1247&#x2013;62. 10.1002/emmm.201302771</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201302771</ArticleId><ArticleId IdType="pmc">PMC3944464</ArticleId><ArticleId IdType="pubmed">23737459</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortes JE, Apperley JF, DeAngelo DJ, et al. . Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. J Hematol Oncol 2018;11 10.1186/s13045-018-0685-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13045-018-0685-2</ArticleId><ArticleId IdType="pmc">PMC6307238</ArticleId><ArticleId IdType="pubmed">30587215</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. . The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (phase III). J Neurol Sci 1999;169:13&#x2013;21. 10.1016/S0022-510X(99)00210-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa J, Swash M, de Carvalho M, et al. . Awaji criteria for the diagnosis of amyotrophic lateral sclerosis:a systematic review. Arch Neurol 2012;69:1410&#x2013;6. 10.1001/archneurol.2012.254</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2012.254</ArticleId><ArticleId IdType="pubmed">22892641</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaki T, Clive S, Weir CJ. Principles of dose finding studies in cancer: a comparison of trial designs. Cancer Chemother Pharmacol 2013;71:1107&#x2013;14. 10.1007/s00280-012-2059-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00280-012-2059-8</ArticleId><ArticleId IdType="pmc">PMC3636432</ArticleId><ArticleId IdType="pubmed">23299793</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesar V, Ciechanowski K, Pei Y, et al. . Bosutinib versus placebo for autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2017;28:3404&#x2013;13. 10.1681/ASN.2016111232</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2016111232</ArticleId><ArticleId IdType="pmc">PMC5661280</ArticleId><ArticleId IdType="pubmed">28838955</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishiyama A, Niihori T, Warita H, et al. . Comprehensive targeted next-generation sequencing in Japanese familial amyotrophic lateral sclerosis. Neurobiol Aging 2017;53:194.e1&#x2013;194.e8. 10.1016/j.neurobiolaging.2017.01.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.01.004</ArticleId><ArticleId IdType="pubmed">28160950</ArticleId></ArticleIdList></Reference><Reference><Citation>Bali T, Self W, Liu J, et al. . Defining SOD1 ALS natural history to guide therapeutic clinical trial design. J Neurol Neurosurg Psychiatry 2017;88:99&#x2013;105. 10.1136/jnnp-2016-313521</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-313521</ArticleId><ArticleId IdType="pmc">PMC5136332</ArticleId><ArticleId IdType="pubmed">27261500</ArticleId></ArticleIdList></Reference><Reference><Citation>De Schaepdryver M, Jeromin A, Gille B, et al. . Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2018;89:367&#x2013;73. 10.1136/jnnp-2017-316605</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-316605</ArticleId><ArticleId IdType="pubmed">29054919</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F, Steinacker P, Weishaupt JH, et al. . Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2019;90:157&#x2013;64. 10.1136/jnnp-2018-318704</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318704</ArticleId><ArticleId IdType="pubmed">30309882</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K, Van Damme P. Diagnostic and prognostic performance of neurofilaments in ALS. Front Neurol 2018;9:1167 10.3389/fneur.2018.01167</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.01167</ArticleId><ArticleId IdType="pmc">PMC6345692</ArticleId><ArticleId IdType="pubmed">30713520</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>